HEADER APOPTOSIS/INHIBITOR 07-MAY-19 6OVC TITLE HMCL1 INHIBITOR COMPLEX COMPND MOL_ID: 1; COMPND 2 MOLECULE: INDUCED MYELOID LEUKEMIA CELL DIFFERENTIATION PROTEIN MCL- COMPND 3 1; COMPND 4 CHAIN: A; COMPND 5 SYNONYM: BCL-2-LIKE PROTEIN 3,BCL2-L-3,BCL-2-RELATED PROTEIN COMPND 6 EAT/MCL1,MCL1/EAT; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: MCL1, BCL2L3; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI K-12; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 83333 KEYWDS INHIBITOR, MCL1 SMALL MOLECULE COMPLEX, APOPTOSIS, APOPTOSIS- KEYWDS 2 INHIBITOR COMPLEX EXPDTA SOLUTION NMR AUTHOR L.POPPE REVDAT 2 01-MAY-24 6OVC 1 REMARK REVDAT 1 22-MAY-19 6OVC 0 JRNL AUTH S.CAENEPEEL,S.P.BROWN,B.BELMONTES,G.MOODY,K.S.KEEGAN,D.CHUI, JRNL AUTH 2 D.A.WHITTINGTON,X.HUANG,L.POPPE,A.C.CHENG,M.CARDOZO,J.HOUZE, JRNL AUTH 3 Y.LI,B.LUCAS,N.A.PARAS,X.WANG,J.P.TAYGERLY,M.VIMOLRATANA, JRNL AUTH 4 M.ZANCANELLA,L.ZHU,E.CAJULIS,T.OSGOOD,J.SUN,L.DAMON, JRNL AUTH 5 R.K.EGAN,P.GRENINGER,J.D.MCCLANAGHAN,J.GONG,D.MOUJALLED, JRNL AUTH 6 G.POMILIO,P.BELTRAN,C.H.BENES,A.W.ROBERTS,D.C.HUANG,A.WEI, JRNL AUTH 7 J.CANON,A.COXON,P.E.HUGHES JRNL TITL AMG 176, A SELECTIVE MCL1 INHIBITOR, IS EFFECTIVE IN JRNL TITL 2 HEMATOLOGIC CANCER MODELS ALONE AND IN COMBINATION WITH JRNL TITL 3 ESTABLISHED THERAPIES. JRNL REF CANCER DISCOV V. 8 1582 2018 JRNL REFN ESSN 2159-8290 JRNL PMID 30254093 JRNL DOI 10.1158/2159-8290.CD-18-0387 REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : MOE REMARK 3 AUTHORS : CCG REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: THE AUTHOR STATES THAT THE SMALL REMARK 3 MOLECULE - PROTEIN COMPLEX WAS OBTAINED BY LIGAND-PROTEIN NOE REMARK 3 CONSTRAINTS DOCKING OF A SMALL MOLECULE TO A PREVIOUSLY OBTAINED REMARK 3 NMR STRUCTURE OF THE APO FORM (PDB ENTRY 2MHS). REMARK 4 REMARK 4 6OVC COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 08-MAY-19. REMARK 100 THE DEPOSITION ID IS D_1000241297. REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 298; 310 REMARK 210 PH : 7.4; 7.4 REMARK 210 IONIC STRENGTH : 50; 50 REMARK 210 PRESSURE : 1 ATM; 1 ATM REMARK 210 SAMPLE CONTENTS : 0.5 MM [U-99% 13C; U-99% 15N] REMARK 210 HUMAN MCL1 PROTEIN, 0.5 MM SMALL REMARK 210 MOLECULE, 20 MM SODIUM PHOSPHATE, REMARK 210 50 MM SODIUM CHLORIDE, 90% H2O/ REMARK 210 10% D2O; 0.5 MM [U-99% 13C; U-99% REMARK 210 15N] HMCL1 PROTEIN, 0.25 MG/L REMARK 210 SMALL MOLECULE, 90% H2O/10% D2O REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : 2D X-FILTERED NOESY; 2D X REMARK 210 FILTERED NOESY-HSQC; 2D HSQC- REMARK 210 NOESY REMARK 210 SPECTROMETER FIELD STRENGTH : 800 MHZ REMARK 210 SPECTROMETER MODEL : AVANCE REMARK 210 SPECTROMETER MANUFACTURER : BRUKER REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : TOPSPIN 3.0, MATLAB REMARK 210 METHOD USED : SIMULATED ANNEALING REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : 1 REMARK 210 CONFORMERS, NUMBER SUBMITTED : 1 REMARK 210 CONFORMERS, SELECTION CRITERIA : STRUCTURES WITH THE LOWEST REMARK 210 ENERGY REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 1 REMARK 210 REMARK 210 REMARK: NULL REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 26 143.99 64.70 REMARK 500 ARG A 32 -119.37 52.95 REMARK 500 LEU A 63 -21.78 -140.53 REMARK 500 PHE A 85 -81.87 -85.84 REMARK 500 SER A 86 -103.17 53.25 REMARK 500 VAL A 89 128.50 61.87 REMARK 500 TRP A 92 -5.29 63.77 REMARK 500 GLU A 115 -25.94 -145.15 REMARK 500 PHE A 150 -69.58 -129.30 REMARK 500 ASP A 154 35.67 -87.74 REMARK 500 HIS A 159 -166.00 49.89 REMARK 500 HIS A 160 87.09 61.40 REMARK 500 HIS A 163 -91.10 56.27 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue N8J A 201 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2MHS RELATED DB: PDB REMARK 900 RELATED ID: 30610 RELATED DB: BMRB REMARK 900 HMCL1 INHIBITOR COMPLEX DBREF 6OVC A 2 158 UNP Q07820 MCL1_HUMAN 171 327 SEQADV 6OVC MET A 1 UNP Q07820 INITIATING METHIONINE SEQADV 6OVC SER A 117 UNP Q07820 CYS 286 CONFLICT SEQADV 6OVC HIS A 159 UNP Q07820 EXPRESSION TAG SEQADV 6OVC HIS A 160 UNP Q07820 EXPRESSION TAG SEQADV 6OVC HIS A 161 UNP Q07820 EXPRESSION TAG SEQADV 6OVC HIS A 162 UNP Q07820 EXPRESSION TAG SEQADV 6OVC HIS A 163 UNP Q07820 EXPRESSION TAG SEQADV 6OVC HIS A 164 UNP Q07820 EXPRESSION TAG SEQRES 1 A 164 MET GLU ASP GLU LEU TYR ARG GLN SER LEU GLU ILE ILE SEQRES 2 A 164 SER ARG TYR LEU ARG GLU GLN ALA THR GLY ALA LYS ASP SEQRES 3 A 164 THR LYS PRO MET GLY ARG SER GLY ALA THR SER ARG LYS SEQRES 4 A 164 ALA LEU GLU THR LEU ARG ARG VAL GLY ASP GLY VAL GLN SEQRES 5 A 164 ARG ASN HIS GLU THR ALA PHE GLN GLY MET LEU ARG LYS SEQRES 6 A 164 LEU ASP ILE LYS ASN GLU ASP ASP VAL LYS SER LEU SER SEQRES 7 A 164 ARG VAL MET ILE HIS VAL PHE SER ASP GLY VAL THR ASN SEQRES 8 A 164 TRP GLY ARG ILE VAL THR LEU ILE SER PHE GLY ALA PHE SEQRES 9 A 164 VAL ALA LYS HIS LEU LYS THR ILE ASN GLN GLU SER SER SEQRES 10 A 164 ILE GLU PRO LEU ALA GLU SER ILE THR ASP VAL LEU VAL SEQRES 11 A 164 ARG THR LYS ARG ASP TRP LEU VAL LYS GLN ARG GLY TRP SEQRES 12 A 164 ASP GLY PHE VAL GLU PHE PHE HIS VAL GLU ASP LEU GLU SEQRES 13 A 164 GLY GLY HIS HIS HIS HIS HIS HIS HET N8J A 201 61 HETNAM N8J (2S)-N-(BENZYLSULFONYL)-4-(CYCLOBUTYLMETHYL)-2-(2,4- HETNAM 2 N8J DICHLOROPHENYL)-3,4-DIHYDRO-2H-1,4-BENZOXAZINE-6- HETNAM 3 N8J CARBOXAMIDE FORMUL 2 N8J C27 H26 CL2 N2 O4 S HELIX 1 AA1 LEU A 5 THR A 22 1 18 HELIX 2 AA2 GLY A 34 GLY A 48 1 15 HELIX 3 AA3 HIS A 55 GLY A 61 1 7 HELIX 4 AA4 GLU A 71 SER A 76 1 6 HELIX 5 AA5 LEU A 77 ARG A 79 5 3 HELIX 6 AA6 VAL A 80 SER A 86 1 7 HELIX 7 AA7 ILE A 95 ILE A 112 1 18 HELIX 8 AA8 ILE A 118 LYS A 133 1 16 HELIX 9 AA9 ASP A 135 ARG A 141 1 7 HELIX 10 AB1 ARG A 141 HIS A 151 1 11 HELIX 11 AB2 GLU A 153 GLY A 157 5 5 SITE 1 AC1 8 HIS A 55 MET A 62 LEU A 66 VAL A 84 SITE 2 AC1 8 ARG A 94 THR A 97 LEU A 98 PHE A 101 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000